Stanford Cancer Center Thoracic CRG Click here to print this page (PDF) 1 July 2015 Non Small Cell Lung Cancer (NSCLC) Stage III Met - IV 2nd Line Failed Therapy LUN0044 Phase I Erlotinib and Dovitinib (TKI258) in Advanced Nonsmall Cell Lung Cancer (NSCLC) PI: Wakelee Stanford EGFR Mutation; Failed TK1 PD-L1 Positive LUN0063 Phase 1 MEDI4736 in Advanced Solid Tumors PI: Wakelee MedImmune 1st Priority ECOGS1400 Phase II/III Biomarker in Second Line Therapy of Squamous Cell Lung Cancer (Screening Step) LUN0069 Phase III Oral Rociletinib Monotherapy vs Cytotoxic Chemotherapy in Mutant EGFR NSCLC PI: Wakelee Pending PI: Wakelee Pending 2nd Priority Metastatic Brain ALK + VAR0098 Phase I First-inHuman DoseEscalation/ Safety/ Tolerability/ Pharmacokinetic s of X-396 in Solid Tumors PI: Wakelee Xcovery Metastatic Brain METS0002 Phase II Oral Ceritinib Tx in ALK-Positive NSCLC Metastatic to the Brain and/or to Leptomeninges PI: Neal Pending LUN0067 Phase 2 Etirinotecan Pegol (NKTR-102) in Adv. Lung Cancer and Refractory Brain Mets PI: Neal Stanford On Gefitinib VAR0069 IRESSA™Gefi tinib for Continued Tx of Patients Who Are Benefiting / Have Benefited from Gefitinib Tx PI: Wakelee AstraZeneca KEY Pending Open for Enrollment Observational Study Optional Path Link Extension Study Trial Posting Enrollment on Hold Please mark up a copy using black ink and fax changes to 725-9204